CDKN2B and cancer: Given the availability of clinical trials targeting cancers with MTAP loss (online supplemental table 3), we performed IHC to test whether protein expression in these five cases was retained, but we found that only the MTAP-CDKN2B truncation led to protein loss, thus potentially having a clinical impact predisposing to sensitivity to MTAP targeted treatment strategies.